6. WHY WOULD SYMPTOMS PERSIST AFTER ANTIBIOTIC TREATMENT FOR LYME DISEASE?

2017 ◽  
pp. 142-158
Keyword(s):  
Lyme Disease ◽  
Antibiotic Treatment

Insufficient evidence to deny antibiotic treatment to chronic Lyme disease patients

2009 ◽  
Vol 72 (6) ◽  
pp. 688-691 ◽  
Author(s):  
Daniel J. Cameron
Keyword(s):  
Lyme Disease ◽  
Antibiotic Treatment ◽  
Insufficient Evidence ◽  
Chronic Lyme Disease

scholarly journals Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease

2001 ◽  
Vol 45 (3) ◽  
pp. 936-937 ◽  
Author(s):  
Charles S. Pavia ◽  
Gary P. Wormser ◽  
John Nowakowski ◽  
Anthony Cacciapuoti
Keyword(s):  
Animal Model ◽  
Lyme Disease ◽  
Borrelia Burgdorferi ◽  
Antibiotic Treatment ◽  
Murine Model ◽  
C3h Mice

ABSTRACT The MICs of evernimicin at which 90% of Borrelia burgdorferi patient isolates were inhibited ranged from 0.1 to 0.5 μg/ml. Evernimicin was as effective as ceftriaxone againstB. burgdorferi in a murine model of experimental Lyme disease. As assessed by culturing the urinary bladders of infected C3H mice, no live Borrelia isolates were recoverable following antibiotic treatment.

Antibiotic Treatment for Chronic Lyme Disease—Say No to the DRESS

2016 ◽  
Vol 176 (12) ◽  
pp. 1745 ◽  
Author(s):  
Clifford M. Marks ◽  
John E. Nawn ◽  
Julie A. Caplow
Keyword(s):  
Lyme Disease ◽  
Antibiotic Treatment ◽  
Chronic Lyme Disease

scholarly journals Patients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study Enrollment

2020 ◽  
Vol 65 (1) ◽  
pp. e01895-20
Author(s):  
Gary P. Wormser ◽  
Donna McKenna ◽  
Eliana Jacobson ◽  
Elayna M. Shanker ◽  
Keith D. Shaffer ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Antibiotic Treatment ◽  
Symptom Severity ◽  
Research Study ◽  
Erythema Migrans ◽  
The United States ◽  
Subjective Symptoms ◽  
Study Enrollment ◽  
Symptom Severity Score ◽  
The Impact

ABSTRACTErythema migrans is the most common clinical manifestation of Lyme disease, with concomitant subjective symptoms occurring in ∼65% of cases in the United States. We evaluated the impact of having been started on antibiotic treatment before study enrollment on 12 particular symptoms for 38 subjects with erythema migrans versus 52 untreated subjects. There were no significant differences in the frequency of having at least one symptom or in the symptom severity score on study entry. However, the frequency of having at least one symptom was significantly greater for those who had received <7 days of antibiotic treatment than for those who had been treated for ≥7 days (23/24 [95.8%] versus 8/14 [57.1%], P = 0.006). In addition, the percentage of subjects who were males was significantly lower among the group on treatment than among the untreated study subjects (13/38 [34.2%] versus 34/52 [65.4%], P = 0.005). In conclusion, based on these findings, combining untreated and treated groups of patients with erythema migrans for research study analyses may have limitations and, depending on the study objectives, might not be preferred. Additional studies are warranted to better understand the day-to-day impact of antibiotic treatment on the presence, type, and severity of symptoms in patients with early Lyme disease.

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease

2001 ◽  
Vol 345 (2) ◽  
pp. 85-92 ◽  
Author(s):  
Mark S. Klempner ◽  
Linden T. Hu ◽  
Janine Evans ◽  
Christopher H. Schmid ◽  
Gary M. Johnson ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Antibiotic Treatment ◽  
Controlled Trials ◽  
Persistent Symptoms ◽  
History Of

scholarly journals A Comparison of Lyme Disease Serologic Test Results From 4 Laboratories in Patients With Persistent Symptoms After Antibiotic Treatment

2014 ◽  
Vol 59 (12) ◽  
pp. 1705-1710 ◽  
Author(s):  
B. A. Fallon ◽  
M. Pavlicova ◽  
S. W. Coffino ◽  
C. Brenner
Keyword(s):  
Lyme Disease ◽  
Antibiotic Treatment ◽  
Test Results ◽  
Serologic Test ◽  
Persistent Symptoms

Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of ‘chronic Lyme disease’

2016 ◽  
Vol 72 (2) ◽  
pp. 133-137 ◽  
Author(s):  
Maarten De Wilde ◽  
Marijn Speeckaert ◽  
Rutger Callens ◽  
Wim Van Biesen
Keyword(s):  
Lyme Disease ◽  
Hemolytic Anemia ◽  
Antibiotic Treatment ◽  
Chronic Lyme Disease ◽  
Immune Hemolytic Anemia ◽  
Life Threatening ◽  
Life Threatening Complication
Sign in / Sign up

Export Citation Format

Share Document